%0 Journal Article
%A Poveda, E
%A Hernández-Quero, J
%A Pérez-Elías, M J
%A Ribas, M A
%A Martínez-Madrid, O J
%A Flores, J
%A Navarro, J
%A Gutiérrez, F
%A García-Deltoro, M
%A Imaz, A
%A Ocampo, A
%A Artero, A
%A Blanco, F
%A Bernal, E
%A Pasquau, J
%A Mínguez-Gallego, C
%A Pérez, N
%A Aiestaran, A
%A García, F
%A Paredes, R
%A PROTEST study group
%T Genotypic tropism testing of proviral DNA to guide maraviroc initiation in aviraemic subjects: 48-week analysis of results from the PROTEST study.
%D 2016
%U http://hdl.handle.net/10668/10725
%X Maraviroc (MVC) is a suitable drug for aviraemic subjects on antiretroviral treatment (ART) developing toxicity. Its prescription requires prior tropism testing. It is unknown if proviral DNA genotypic tropism testing is reliable for guiding MVC initiation in aviraemic subjects, so this study was carried out to address this issue. PROTEST was a phase 4, prospective, single-arm clinical trial carried out in 24 HIV care centres in Spain. MVC-naïve HIV-1-infected patients with HIV-1 RNA  50 copies/mL. Tropism results were available for 141 of 175 (80.6%) subjects screened: 60% had R5 and 85% of these (n = 74) were finally included in the study. Previous ART included protease inhibitors (PIs) in 62% of subjects, nonnucleoside reverse transcriptase inhibitors (NNRTIs) in 36%, and integrase inhibitors (INIs) in 2%. Main reasons for treatment change were dyslipidaemia (42%), gastrointestinal symptoms (22%) and liver toxicity (15%). MVC was given alongside tenofovir (TDF)/emtricitabine (FTC) (54%) and abacavir (ABC)/lamivudine (3TC) (40%) in most patients. Eighty-four per cent of patients maintained a viral load  Initiation of MVC plus two NRTIs in aviraemic subjects based on genotypic tropism testing of proviral HIV-1 DNA is associated with low rates of virological failure for up to 1 year.
%K Maraviroc
%K genotypic tropim
%K proviral DNA
%~